Cardiac resynchronization therapy (CRT) is of little value to 40% of patients who are candidates for the therapy under current guidelines, according to a study published Monday in the Archives of Internal Medicine. Ilke Sipahi, MD, and colleagues from University Hospitals Case Medical Center and Case Western Reserve University conducted a metanalysis of five randomized clinical trials and found that the therapy is helpful for heart failure patients with prolonged QRS (an electrocardiogram measurement), but not those with QRS measurements of moderate duration. CRT devices cost about $25,000 and are implanted in 60,000 patients annually, according to an article in the June 14 issue of The Wall Street Journal.